RFA-DK-22-011: Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 28, 2022.
From the official notice on Grants.gov, last changed April 13, 2022. Checked November 7, 2026.
- Award ceiling$750,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP30
- Clinical trialsOptional
- Funded byNIDDK
- Median yearly award$233,360
- Typical project length8 years
- P30, Center Core Grant. Shared facilities and services for investigators who already hold research funding on a common theme. Other open P30 notices.
Projects funded under RFA-DK-22-011 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-22-011 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DK-25-010 | April 23, 2024 | Closed July 17, 2024 | Closed |
Key dates
| Posted | April 12, 2022 |
|---|---|
| Deadline | July 28, 2022 |
| Archived by Grants.gov | September 2, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $233,360; it allows up to $750,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research. Information about the currently funded CF Research and Translation Centers may be found at:https://www.niddk.nih.gov/research-funding/research-programs/cystic-fibrosis-research-translation-centers or https://www.cysticfibrosiscenters.org/.
Funded under RFA-DK-22-011 so far
NIH funded 3 projects under RFA-DK-22-011 in fiscal 2023 to 2026, at 3 institutions. The median yearly award was $233,360.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Pilot & Feasibility Core | Emory University | 2026 | $165,423 |
| UAB CFRC Core A: Cell Model and Evaluation Core | University of Alabama at Birmingham | 2026 | $307,981 |
| Personalized Cystic Fibrosis Therapy and Research Center | Cincinnati Childrens Hosp Med Ctr | 2024 | $944,438 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-22-011 still open?
No. It closed on July 28, 2022.
Who can apply for Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)?
Closed July 28, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each.
Who has been funded under RFA-DK-22-011?
NIH RePORTER lists 3 projects funded under RFA-DK-22-011 in fiscal 2023 to 2026, at 3 institutions. The most were at Emory University, University of Alabama at Birmingham, Cincinnati Childrens Hosp Med Ctr.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
- Diabetes Research Centers (P30 Clinical Trial Optional)
- KUH P30 Resource Core Center (P30 Clinical Trial Not Allowed)
- Silvio O. Conte Digestive Diseases Research Core Centers (P30-Clinical Trial Optional)
- Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)
- AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)